NCT00979992 2020-02-19
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
3 trialsNCT00478426 2020-02-17
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00389974 2015-02-16
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed